Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III remibrutinib versus placebo study in generalized myasthenia gravis with open-label extension
NL-OMON59936Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in myasthenia gravis (MG) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living total score. Started May 2025; status: completed.
02
Drugs
remibrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON59936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59936.